|1.||Köker, Esra: 1 article (01/2015)|
|2.||Yavuz Kocaman, Ayşe: 1 article (01/2015)|
|3.||Dönbak, Lale: 1 article (01/2015)|
|4.||Gökçe, Şule: 1 article (01/2015)|
|5.||Kayraldız, Ahmet: 1 article (01/2015)|
|6.||Arda, Bilgin: 1 article (02/2004)|
|7.||Gürel, Ozlem: 1 article (02/2004)|
|8.||Yaimazhan, Tansu: 1 article (02/2004)|
|9.||Tunçel, Mürşide: 1 article (02/2004)|
|10.||Gökengin, Deniz: 1 article (02/2004)|
03/01/1993 - "Clinical efficacy of dirithromycin in acute exacerbations of chronic bronchitis."
01/01/1998 - "Since a high tissue penetration of dirithromycin (D) has been assessed in early studies, the aims of this study were to determine D concentrations in bronchial mucosa and secretions in patients suffering from an acute exacerbation of chronic bronchitis (AECB), to compare intra-individual bronchial mucosa and secretion concentrations and to relate bronchial concentrations of D and clinical efficacy. "
08/01/1997 - "This study shows that a 5-day dirithromycin therapy provides a convenient and efficient dosage regimen in acute exacerbation of chronic bronchitis. "
12/01/1994 - "The aim of this study was to evaluate the concentrations of dirithromycin, a new macrolide antibiotic, in bronchial secretions (BS), bronchial mucosa (BM), epithelial lining fluid (ELF) and serum in 25 patients with acute exacerbation of chronic bronchitis after a 5-day, once-daily, dirithromycin regimen. "
12/01/1994 - "Pulmonary penetration of dirithromycin in patients suffering from acute exacerbation of chronic bronchitis."
|2.||Soft Tissue Infections
03/01/1993 - "Dirithromycin is a recently developed oral antibiotic, and has been shown to be effective in the treatment of respiratory tract, skin and soft tissue infections. "
10/01/1996 - "Controlled single- or double-blind studies were evaluated to assess the efficacy of dirithromycin in the treatment of various upper and lower respiratory tract infections, as well as skin and soft tissue infections. "
08/01/2000 - "Comparative efficacy of 5 days of dirithromycin and 7 days of erythromycin in skin and soft tissue infections."
08/01/2000 - "We investigated the comparative efficacy and safety of dirithromycin and erythromycin in the treatment of skin and soft tissue infections in this double-blind, randomized, multicentre study, in which 439 patients were randomized to treatment with dirithromycin (500 mg daily for 5 days) or erythromycin (250 mg every 6 h for 7 days). "
10/01/1996 - "Clinical efficacy and bacteriologic eradication rates with dirithromycin and erythromycin are comparable for the treatment of respiratory and skin and soft tissue infections due to susceptible pathogens. "
|3.||Pharyngitis (Sore Throat)
03/01/1993 - "Dirithromycin in the treatment of streptococcal pharyngitis."
03/01/1993 - "Clinical efficacy of dirithromycin in pharyngitis and tonsillitis."
09/01/1995 - "The trial of a new antibiotic dirithromycin against acute pharyngitis and tonsillitis for safety and efficacy included 28 patients with acute tonsillitis and pharyngitis. "
01/01/1997 - "In a double-blind, randomized study, dirithromycin, a new macrolide, was compared with penicillin for the treatment of streptococcal pharyngitis. "
01/01/1997 - "Comparison of dirithromycin and penicillin for treatment of streptococcal pharyngitis."
04/01/1998 - "Effect of dirithromycin on Haemophilus influenzae infection of the respiratory mucosa."
07/01/1995 - "[Dirithromycin in the treatment of infections of the lower respiratory tract]."
12/01/1994 - "These findings demonstrate that dirithromycin is concentrated in each of these potential sites of infection for up to 3 days after a 5-day course of therapy. "
12/01/1993 - "After removal of extracellular drug, the efflux (release) of dirithromycin from PMNs was slow; only 10% was released within the first 30 min. This prolonged retention of dirithromycin within phagocytic cells might allow delivery and release of accumulated drug at sites of infection. "
12/01/1993 - "Ingestion of microbial particles (mimicking in vivo infection) modestly inhibited the entry of dirithromycin into PMNs. "
08/01/1997 - "[Double-blind clinical trial comparing 5 days of dirithromycin versus 7 days of diacetylmidecamycin in acute bronchitis and acute exacerbations of chronic bronchitis]."
03/01/1993 - "In acute bronchitis, both drugs were effective with clinical success rates of 93.0% and 95.2% at post-therapy, and 96.9% and 100% at late post-therapy for dirithromycin and erythromycin, respectively. "
03/01/1993 - "A multicentre study comparing the safety and efficacy of dirithromycin with erythromycin in the treatment of bronchitis."
04/01/1996 - "Proven or presumed pathogen eradication rates were 83 and 86% for acute bronchitis patients treated with dirithromycin and erythromycin, respectively. "
03/01/1993 - "The results, in 161 assessable patients (78 taking dirithromycin; 83 taking miocamycin), show that dirithromycin and miocamycin have comparable efficacy and safety in the treatment of bronchitis caused by susceptible bacterial pathogens."
|8.||Penicillin V (Phenoxymethylpenicillin)